H.C. Wainwright raised the firm’s price target on Capricor Therapeutics to $40 from $18 and keeps a Buy rating on the shares. The company is now well-funded beyond the expected regulatory milestones, the analyst tells investors in a research note. The firm believes Capricor’s recent updates provide “critical visibility” to both investors and potential additional partnerships beyond the already signed U.S. and Japan partnership with Nippon Shinyaku.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CAPR:
- Capricor Therapeutics Announces $23 Million Registered Direct Offering
- Capricor Therapeutics sells 4.94M shares at $5.70 in registered direct offering
- Capricor Therapeutics announces Type-B meeting with FDA for CAP-1002
- Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy
- Capricor Therapeutics Appoints Michael Kelliher to Board of Directors